A POC and Dose-Ranging Study of HTD1801 in PSC Patients
Diseases of the Digestive System - Liver
What is the purpose of this trial?
This study evaluates HTD1801 in the treatment of Primary Sclerosing Cholangitis (PSC) in adults. The subjects will be randomised to 3 treatment groups, to receive 500mg, 1000mg and placebo, bid.
- Ages18 - 75 years
- Trial withHighTide Biopharma Pty. Ltd.
- Start Date06/28/2018
- End Date11/29/2018
- Last Updated07/03/2018
- Study HIC#2000022820